<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404989</url>
  </required_header>
  <id_info>
    <org_study_id>APR</org_study_id>
    <nct_id>NCT00404989</nct_id>
  </id_info>
  <brief_title>Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.</brief_title>
  <acronym>APR</acronym>
  <official_title>Antiretroviral Pregnancy Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accord Healthcare, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alvogen Korea</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apotex Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aurobindo Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cipla Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hetero Labs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hikma Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lannett Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lupin Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Macleods Pharmaceuticals, Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prinston Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sigmapharm Laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Strides Shasun Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Syneos Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Antiretroviral Pregnancy Registry (Registry) is to detect any major&#xD;
      teratogenic effect involving any of the Registry drugs when administered to pregnant women.&#xD;
      Registration is voluntary and confidential with information obtained from the health care&#xD;
      provider. A Registry-assigned identifier allows for follow-up capability. Information on&#xD;
      subjects is provided to the Registry prospectively (prior to the outcome of pregnancy being&#xD;
      known) through their health care provider, with follow-up obtained from the health care&#xD;
      provider after the outcome is determined. Providers are strongly urged to enroll their&#xD;
      patients as early in pregnancy as possible to maximize the validity of the data. In addition,&#xD;
      the Registry is very interested in assembling a group of providers who are willing to make a&#xD;
      commitment to report all of their site's antiretroviral pregnancy exposures to the Registry,&#xD;
      thereby assuring all cases can be considered prospective. Providers are encouraged to contact&#xD;
      the Registry for more information about this group. The Registry is informed in its analysis&#xD;
      by other data, for example, retrospective reports and clinical studies.&#xD;
&#xD;
      Given the increasing number of medications and more aggressive approach to therapy, more HIV-&#xD;
      and hepatitis B-infected women may be treated during pregnancy or become pregnant while under&#xD;
      treatment. The paucity of data on use and infant outcomes of antiretroviral therapies during&#xD;
      pregnancy makes this Registry an essential component of the ongoing program of epidemiologic&#xD;
      studies of the safety of these therapies.&#xD;
&#xD;
      Each year the Registry has enrolled approximately 1300-1700 pregnant women in the US exposed&#xD;
      to antiretroviral drugs. This number represents approximately 15% of the 8,700 HIV positive&#xD;
      women who give birth to live infants annually in the US.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following antiretroviral drugs are followed by the Antiretroviral Pregnancy Registry&#xD;
      (APR, Registry) to detect any major teratogenic effect when administered to pregnant women:&#xD;
      abacavir (ZIAGEN®, ABC), abacavir/lamivudine (EPZICOM®, KIVEXA®, EPZ),&#xD;
      abacavir/lamivudine/zidovudine (TRIZIVIR®, TZV), abacavir/dolutegravir/lamivudine (TRIUMEQ®,&#xD;
      TRI), adefovir dipivoxil (HEPSERA®, ADV), amprenavir (AGENERASE®, APV), atazanavir (REYATAZ®,&#xD;
      ATV), atazanavir/cobicistat (EVOTAZ®, EVO), bictegravir/emtricitabine/tenofovir alafenamide&#xD;
      (BIKTARVY®, B/F/TAF), cabotegravir (VOCABRIA®, CABENUVA®, CAB), cobicistat (TYBOST®, COBI),&#xD;
      darunavir (PREZISTA®, DRV), darunavir/cobicistat (PREZCOBIX™, REZOLSTA™, PCX),&#xD;
      darunavir/cobicistat/emtricitabine/tenofovir alafenamide (SYMTUZA®, DCF TAF ), delavirdine&#xD;
      mesylate (RESCRIPTOR®, DLV), didanosine (VIDEX®, VIDEX® EC, ddI), dolutegravir (TIVICAY®,&#xD;
      DTG), dolutegravir/lamivudine (DOVATO®, DTG/RPV), dolutegravir/lamivudine/tenofovir&#xD;
      disoproxil fumarate (ACRIPTEGA/TELADOMYL/TENDOLA, TLD), dolutegravir/rilpivirine (JULUCA™,&#xD;
      DTG/RPV), emtricitabine/tenofovir alafenamide (DESCOVY®, DVY), efavirenz (SUSTIVA®, STOCRIN®,&#xD;
      EFV), efavirenz/emtricitabine/tenofovir disoproxil (ATRIPLA® ATR),&#xD;
      efavirenz/lamivudine/tenofovir disoproxil fumarate (SYMFI LO™, EFV/3TC/TDF), elvitegravir&#xD;
      (VITEKTA®, EVG), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (GENVOYA®, GEN),&#xD;
      elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (STRIBILD®, STB),&#xD;
      emtricitabine (EMTRIVA®, FTC), enfuvirtide (FUZEON®, T-20), entecavir (BARACLUDE®, ETV),&#xD;
      etravirine (INTELENCE®, ETR), fosamprenavir calcium (LEXIVA®, FOS), fostemsavir (RUKOBIA,&#xD;
      FTR), indinavir (CRIXIVAN®, IDV), lamivudine (EPIVIR®, 3TC), lamivudine/raltegravir&#xD;
      (DUTREBIS™, DUT), lamivudine/tenofovir disoproxil fumarate (CIMDUO™, 3TC/TDF),&#xD;
      lamivudine/zidovudine (COMBIVIR®, CBV), lopinavir/ritonavir (KALETRA®, ALUVIA®, LPV/r),&#xD;
      maraviroc (SELZENTRY®, CELSENTRI®, MVC), nelfinavir (VIRACEPT®, NFV), nevirapine (VIRAMUNE®,&#xD;
      VIRAMUNE® XR™, NVP), raltegravir (ISENTRESS®, RAL), rilpivirine (EDURANT®, REKAMBYS®,&#xD;
      CABENUVA®, RPV), rilpivirine/emtricitabine/tenofovir alafenamide (ODEFSEY®,ODE),&#xD;
      rilpivirine/emtricitabine/tenofovir disoproxil (COMPLERA®, CPA; EVIPLERA®, EPA), ritonavir&#xD;
      (NORVIR®, RTV), saquinavir (FORTOVASE®, SQV-SGC), saquinavir mesylate (INVIRASE®, SQV-HGC),&#xD;
      stavudine (ZERIT®, d4T), telbivudine (SEBIVO®, TYZEKA®, LdT), tenofovir alafenamide&#xD;
      (VEMLIDY®, TAF), tenofovir disoproxil fumarate (VIREAD®, TDF), tenofovir disoproxil&#xD;
      fumarate/emtricitabine (TRUVADA®, TVD), tipranavir (APTIVUS®, TPV), zalcitabine (HIVID®,&#xD;
      ddC), and zidovudine (RETROVIR®, ZDV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 1989</start_date>
  <completion_date type="Anticipated">January 2099</completion_date>
  <primary_completion_date type="Anticipated">January 2099</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">24258</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women exposed to antiviral medications during pregnancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Ages Eligible for Study: Women of childbearing age&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Country of origin of report&#xD;
&#xD;
          -  Documentation that the registry drug was taken during pregnancy&#xD;
&#xD;
          -  Sufficient information to determine if the pregnancy is being prospectively or&#xD;
             retrospectively registered&#xD;
&#xD;
          -  Date the pregnancy was registered&#xD;
&#xD;
          -  Source of report (patient or health care provider)&#xD;
&#xD;
          -  Whether the pregnancy outcome is already known or delivery is still pending&#xD;
&#xD;
          -  Timing of the prenatal exposure to the registry medication (no broader than which&#xD;
             trimester)&#xD;
&#xD;
          -  Sufficient patient identifier relevant to reporter to allow for follow-up&#xD;
&#xD;
          -  Was patient involved in a study at the time of prenatal exposure&#xD;
&#xD;
          -  Full reporter contact information (name, address, etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who were not exposed to registry medications during pregnancy&#xD;
&#xD;
          -  Male patients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica D Albano, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taylor Cook</last_name>
    <phone>800-258-4263</phone>
    <email>SM_APR@APRegistry.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Registry Coordinating Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://apregistry.com</url>
    <description>Download: data forms to register patients, Semi-Annual Interim Report, product package inserts, organizational links, guidelines, bibliography</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

